Tralokinumab | Search results | NICE

Showing 1 to 7 of 7 results for tralokinumab

Sort by

Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis (TA814)
Evidence-based recommendations on abrocitinib (Cibinqo), tralokinumab (Adtralza) or upadacitinib (Rinvoq) for treating moderate to severe atopic dermatitis.
Result type
Technology appraisal guidance
Published
3 August 2022
View recommendations for TA814
Show all sections
Sections for TA814
Lebrikizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA986)
Evidence-based recommendations on lebrikizumab (Ebglyss) for treating moderate to severe atopic dermatitis in people 12 years and over.
Result type
Technology appraisal guidance
Published
10 July 2024
View recommendations for TA986
Show all sections
Sections for TA986
Nemolizumab for treating moderate to severe atopic dermatitis in people 12 years and over (TA1077)
Evidence-based recommendations on nemolizumab (Nemluvio) for treating moderate to severe atopic dermatitis in people 12 years and over.
Result type
Technology appraisal guidance
Published
2 July 2025
View recommendations for TA1077
Show all sections
Sections for TA1077
Tralokinumab for treating moderate to severe atopic dermatitis [ID3734]
Discontinued Reference number: GID-TA10596
Result type
Technology appraisal guidance
Status
Discontinued
Upadacitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3733]
Discontinued Reference number: GID-TA10597
Result type
Technology appraisal guidance
Status
Discontinued
Abrocitinib for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3768]
Discontinued Reference number: GID-TA10764
Result type
Technology appraisal guidance
Status
Discontinued
Tralokinumab for treating moderate to severe atopic dermatitis in people aged 12 and over [ID3823]
Discontinued Reference number: GID-TA10702
Result type
Technology appraisal guidance
Status
Discontinued